NVCT
Nuvectis Pharma, Inc.
Key Financials
Operating Income
$-27574000
↓ 38.9%
Net Income
$-26442000
↓ 39.2%
Total Assets
$31.7M
↑ 70.4%
EPS (Diluted)
$-1.32
↓ 18.9%
Total Liabilities
$13.3M
↑ 49.5%
Shareholders' Equity
$18.4M
↑ 89.6%
Cash & Equivalents
$31.6M
↑ 70.7%
Dividends/Share
$0.00
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/6/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 10-Q | 8/4/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 8-K | 6/30/2026 | View on SEC |
| 424B5 | 6/30/2026 | View on SEC |
| 424B5 | 6/29/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NVCT |
| Company Name | Nuvectis Pharma, Inc. |
| CIK | 1875558 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 360-837-7232 |